Oren Gilad - Aug 23, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
President, CEO, Director
Signature
/s/ John Hamill, Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Aug 23, 2022
Transactions value $
$0
Form type
4
Date filed
3/13/2023, 06:30 PM
Previous filing
Aug 1, 2022
Next filing
Mar 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Conversion of derivative security $0 +6.05M +1830.11% $0.00 6.38M Aug 23, 2022 Direct F2
transaction APRE Common Stock Award $0 +4K +1.25% $0.00 323K Mar 9, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Series A Non-Voting Convertible Preferred Stock Conversion of derivative security $0 -605K -100% $0.00* 0 Aug 23, 2022 Common Stock 6.05M Direct F2
transaction APRE Stock Options (Right to Buy) Award $0 +16K $0.00 16K Mar 9, 2023 Common Stock 16K $5.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 9, 2024 until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock.
F3 Twenty-five percent of these options vest on March 9, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F4 Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023.

Remarks:

Exhibit 24 - Power of Attorney